David A. Ricks

Chair, President, and Chief Executive Officer at ELI LILLY &

Board

Since 2017

Age

57 years

Tenure

Has been with LLY for 28 years, starting in 1996 and progressing through roles in marketing, sales, international leadership, as President of Lilly USA, and as Senior Vice President & President of Lilly Bio-Medicines before being named Chair, President, and CEO in 2017.

Also at ELI LILLY &

Alonzo Weems

Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer

Anat Hakim

Executive Vice President, General Counsel, and Secretary

Anne White

Executive Vice President and President of Lilly Neuroscience

About

David A. Ricks serves as the Chair, President, and Chief Executive Officer of Eli Lilly and Company, bringing a wealth of experience from a 28-year career at the firm. At 57 years old as of 2024 , his leadership reflects decades of service and strategic guidance across various divisions of the company.

Throughout his distinguished career, he has held key roles including positions in marketing, sales, and international operations, progressing from significant leadership roles such as President of Lilly USA and Senior Vice President & President of Lilly Bio-Medicines to ultimately leading the company as CEO in 2017.

In addition to his executive roles at LLY, he contributes to the broader industry by serving on the board of directors for Adobe Inc. and participating in several industry organizations such as the Pharmaceutical Research and Manufacturers of America and the International Federation of Pharmaceutical Manufacturers & Associations.

$LLY Performance Under David A. Ricks

Past Roles

Organization	Role	Date Range	Details [N/A]
Eli Lilly and Company	Senior Vice President and President, Lilly Bio-Medicines	2012–2016	N/A
Eli Lilly and Company	President, Lilly USA	2009–2012	N/A
Eli Lilly and Company	President and General Manager, Lilly China	1996–2009	N/A
Eli Lilly and Company	General Manager, Lilly Canada	1996–2009	N/A

External Roles

Organization	Role	Date Range	Details [N/A]
Adobe Inc.	Director	N/A	N/A

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Salary	$1,621,154	Annually (2023)	Fixed base salary
Nonqualified Savings Plan Contributions	$77,469	Annually (2023)	Employer contribution
401(k) Contributions	$19,800	Annually (2023)	Derived from total matching contributions of $97,269 minus Nonqualified Savings Plan Contributions
Personal Use of Corporate Aircraft	$65,804	Annually (2023)	Incremental cost for personal use
HSR Filing Fee Reimbursement	$100,000	Annually (2023)	Reimbursed fee processed as imputed income for tax withholding

Performance Compensation

Data from FY 2023

Non-Equity Incentive Plan Compensation (Bonus Plan)

Metric [Weight] (%)	Target/Threshold Detail	Actual Result/Multiplier	Payout Amount (USD)
Revenue [25%]	Not explicitly provided	–	–
EPS [50%]	Target: 2.0% annual growth (cumulative goal not detailed)	–	–
Pipeline Progress [25%]	Targets include: 2 new drug first approvals; 9 other approvals (among other metrics)	Pipeline multiple: 1.86	–
Overall Bonus	Payout Multiple: 181% of target	–	$4,401,433
Evaluation Period: Annual 2023; no vesting as award is cash-based

2023-2025 Performance Awards (EPS-Based)

Metric [Detail]	Value	Notes
Grant Date	Feb 10, 2023	–
Grant Date Fair Value (USD)	$6,327,750	Determined at grant date
Performance Metric	EPS Growth	Assessed via cumulative 2-year EPS performance
Threshold Shares	7,983	0% payout if cumulative EPS ≤ $16.12
Target Shares	15,966	100% payout if cumulative EPS = $18.21
Maximum Shares	31,932	200% payout if cumulative EPS ≥ $21.57
Vesting Schedule	February 2026	Contingent upon meeting employment requirements

2023-2025 Shareholder Value Awards (SVA)

Metric [Detail]	Value	Notes
Grant Date	Feb 10, 2023	–
Grant Date Fair Value (USD)	$6,256,250	–
Weighted-Average Fair Value (USD)	$349.63	Derived via Monte Carlo simulation
Performance Metric	Final Stock Price	Based on 3-year stock performance
Payout Threshold	Final Price < $347.53	Results in 0% payout
Payout Target	Final Price = $441.12	100% payout
Payout Maximum	Final Price > $584.73	200% payout
Target Shares	19,512	–
Maximum Shares	39,024	200% of target
Vesting Schedule	December 31, 2025	Subject to a one-year post-vesting holding requirement

2023-2025 Relative Value Awards (RVA)

Metric [Detail]	Value	Notes
Grant Date	Feb 10, 2023	–
Grant Date Fair Value (USD)	$6,256,250	–
Performance Metric	Relative TSR vs. peer group	Assesses total shareholder return relative to peers
Payout Threshold	≤ -24.0 pp difference	Yields 0% payout
Payout Target	At Peer Median TSR	Yields 100% payout
Payout Maximum	≥ +30.0 pp difference	Yields 200% payout
Target Shares	15,721	–
Maximum Shares	31,442	200% of target
Vesting Schedule	December 31, 2025	Contingent on continued employment

Interviews

Eli Lilly CEO David Ricks on Q1 results, weight loss drug competition and status of weight-loss pill

CNBC Television7:08 minMay 1, 2025

CNBC Television

7:08 min

May 1, 2025

David A. Ricks

Also at ELI LILLY &

About

$LLY Performance Under David A. Ricks

Past Roles

External Roles

Fixed Compensation

Performance Compensation

Non-Equity Incentive Plan Compensation (Bonus Plan)

2023-2025 Performance Awards (EPS-Based)

2023-2025 Shareholder Value Awards (SVA)

2023-2025 Relative Value Awards (RVA)

Interviews

Eli Lilly CEO David Ricks on Q1 results, weight loss drug competition and status of weight-loss pill

Eli Lilly CEO David Ricks: Projecting 32% total growth for company in 2025

The David Rubenstein Show: Eli Lilly CEO Dave Ricks

David A Ricks, Chair and Chief Executive Officer of Eli Lilly and Company

Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine

Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result

Eli Lilly CEO on $27 billion investment in U.S. manufacturing expansion

Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing

Eli Lilly CEO David Ricks on Q3 results: The underlying growth story is fantastic

Seeing More Acceptance Of Mounjaro Across Markets: Eli Lilly's Global CEO David Ricks | CNBC TV19

A Breakthrough in Health: How GLP-1s Are Redefining Pharma with David Ricks and Fatima Cody Stanford

Eli Lilly CEO David Ricks on GLP-1 and obesity drugs

Eli Lilly CEO David Ricks on $.5.3 billion weight loss drug investment

Eli Lilly CEO David Ricks on Q2 results: Seeing unbelievable demand for Zepbound and Mounjaro

Vast utility for weight loss drugs will more than pay for themselves, says Eli Lilly CEO David Ricks

Eli Lilly CEO on Fighting Obesity, Developing New Drugs